Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex
A Placebo-Controlled Randomized Clinical Trial

Elizabeth A. Thiele, MD, PhD; E. Martina Bebin, MD, MPA; Hari Bhathal, MD; Floor E. Jansen, MD; Katarzyna Kotulska, MD, PhD; John A. Lawson, BMed, PhD; Finbar J. O’Callaghan, MBChB, PhD; Michael Wong, MD, PhD; Farhad Sahebkar, MD; Daniel Checketts, MSc; Volker Knappertz, MD; for the GWPCARE6 Study Group

**IMPORTANCE** Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as tuberous sclerosis complex (TSC).

**OBJECTIVE** To evaluate efficacy and safety of 25-mg/kg/day and 50-mg/kg/day cannabidiol dosages vs placebo against seizures associated with TSC.

**DESIGN, SETTING, AND PARTICIPANTS** This double-blind, placebo-controlled randomized clinical trial (GWPCARE6) enrolled patients between April 6, 2016, and October 4, 2018; follow-up was completed on February 15, 2019. The trial was conducted at 46 sites in Australia, Poland, Spain, the Netherlands, United Kingdom, and United States. Eligible patients (aged 1-65 years) were those with a clinical diagnosis of TSC and medication-resistant epilepsy who had had at least 8 TSC-associated seizures during the 4-week baseline period, with at least 1 seizure occurring in at least 3 of the 4 weeks, and were currently taking at least 1 antiepileptic medication.

**INTERVENTIONS** Patients received oral cannabidiol at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD50) or a matched placebo for 16 weeks.

**MAIN OUTCOMES AND MEASURES** The prespecified primary outcome was the change from baseline in number of TSC-associated seizures for cannabidiol vs placebo during the treatment period.

**RESULTS** Of 255 patients screened for eligibility, 31 were excluded and 224 were randomized. Of the 224 included patients (median [range] age, 11.4 [1.1-56.8] years; 93 female patients [41.5%]), 75 were randomized to CBD25, 73 to CBD50, and 76 to placebo, with 201 completing treatment. The percentage reduction from baseline in the type of seizures considered the primary end point was 48.6% (95% CI, 40.4%-55.8%) for the CBD25 group, 47.5% (95% CI, 39.0%-54.8%) for the CBD50 group, and 26.5% (95% CI, 14.9%-36.5%) for the placebo group; the percentage reduction from placebo was 30.1% (95% CI, 13.9%-43.3%; *P* < .001) for the CBD25 group and 28.5% (95% CI, 11.9%-42.0%; nominal *P* = .002) for the CBD50 group. The most common adverse events were diarrhea (placebo group, 19 [25%]; CBD25 group, 23 [31%]; CBD50 group, 41 [56%]) and somnolence (placebo group, 7 [9%]; CBD25 group, 10 [13%]; CBD50 group, 19 [26%]), which occurred more frequently with cannabidiol than placebo. Eight patients in CBD25 group, 10 in CBD50 group, and 2 in the placebo group discontinued treatment because of adverse events. Twenty-eight patients taking cannabidiol (18.9%) had elevated liver transaminase levels vs none taking placebo.

**CONCLUSIONS AND RELEVANCE** Cannabidiol significantly reduced TSC-associated seizures compared with placebo. The 25-mg/kg/day dosage had a better safety profile than the 50-mg/kg/day dosage.

**TRIAL REGISTRATION** ClinicalTrials.gov Identifier: NCT02544763

JAMA Neurol. doi:10.1001/jamaneurol.2020.4607
Published online December 21, 2020.

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Group Information:** The GWPCARE6 Study Group members are listed at the end of this article.

**Corresponding Author:** Elizabeth A. Thiele, MD, PhD, Pediatric Epilepsy Program, Massachusetts General Hospital, 175 Cambridge St, Ste 340, Boston, MA 02114 (ethiele@mgh.harvard.edu).
Tuberous sclerosis complex (TSC) is a disorder caused by autosomal-dominant sequence variations in the TSC1 and/or TSC2 genes, resulting in upregulation of the mechanistic target of rapamycin (mTOR) pathway with subsequent excessive cell growth and proliferation.1-4 Tuberous sclerosis complex is characterized by the occurrence of benign hamartomas in multiple organ systems, most frequently in brain, skin, kidneys, lungs, heart, and eyes.1-5 Incidence of TSC is estimated at 1 in 6000 live births, affecting 1 to 2 million individuals worldwide.6,7

Epilepsy is the most common neurologic manifestation of TSC, affecting approximately 85% of patients, with onset often during infancy.8-12 Patients experience focal seizures and infantile spasms as infants and a variety of other seizures during their lifetime.10,11 Despite several treatment options for TSC-associated seizures—including antiepileptic drugs such as vigabatrin, the mTOR inhibitor everolimus, surgical procedures, and dietary therapy14—more than 60% of patients have treatment-resistant epilepsy,13 which is associated with neurodevelopmental disorders, including autism and intellectual disability.11,15

Cannabidiol is approved as Epidiolex in the US for treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or TSC in patients 1 year and older, and as Epidyolex in the European Union in conjunction with clobazam for Lennox-Gastaut syndrome and Dravet syndrome in patients 2 years and older.16,17 Efficacy of cannabidiol was first demonstrated against Dravet syndrome–associated and Lennox-Gastaut syndrome–associated seizures.16-21 On the basis of data from patients with TSC in an expanded-access program,22 we conducted a placebo-controlled randomized clinical trial to assess efficacy and safety of add-on cannabidiol for the treatment of TSC-associated seizures (primarily focal seizures) in children and adults.

Methods

Study Design and Participants

This was a phase 3, international, double-blind, parallel-group randomized clinical trial of add-on cannabidiol vs placebo in patients with TSC and drug-resistant epilepsy. The trial consisted of a 4-week baseline period, a 16-week treatment period (4 weeks for dose escalation [titration period] followed by 12 weeks of stable dosing [maintenance period]), a taper period of up to 10 days, and a 4-week safety follow-up (eFigure 1 in Supplement 1). The protocol was approved by an institutional review board or ethics committee at each participating site and conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Tripartite Guideline on Good Clinical Practice. All patients or caregivers provided written informed consent, and patients developmentally mature enough to understand the trial provided assent. All authors vouch for the accuracy of the reported results and adherence to the protocol. The manuscript was written by all authors, 3 of whom are GW Pharmaceuticals employees (F.S., D.C., and V.K.).

Eligible patients (aged 1-65 years) with a definite clinical diagnosis of TSC and medication-resistant epilepsy had at least 8 TSC-associated seizures during the 4-week baseline period with at least 1 seizure occurring in at least 3 of the 4 weeks and were taking at least 1 antiepileptic medication. Key exclusion criteria were a history of nonepileptic seizures, clinically significant illness other than epilepsy, epilepsy surgery in the 6 months before screening, felbamate use for less than 1 year before screening, and use of oral mTOR inhibitors. Details of eligibility criteria are provided in eTable 1 in Supplement 1.

Randomization, Concealment, and Masking

After screening and the baseline period, eligible patients were randomized equally to receive a pharmaceutical formulation of highly purified cannabidiol derived from Cannabis sativa L. (100 mg/mL oral solution; Epidiolex in the US; Epidyolex in the European Union [GW Research Ltd]) at 25 mg/kg of body weight per day (CBD25 group), 50 mg/kg/day (CBD50 group), or placebo. Patients in the placebo group were subdivided to receive a placebo matching either the 25-mg/kg/day or 50-mg/kg/day dosage of CBD. The placebo groups were pooled for reporting efficacy and safety results. The randomization schedule was created by an independent statistician and stratified by age group (1-6, 7-11, 12-17, and 18-65 years). Cannabidiol solutions and placebo solutions (excipients alone) were provided in identical 100-mL amber glass bottles.

Procedures

Study drugs were administered twice daily in equally divided doses with a faster titration schedule than prior studies: doses started at 5 mg/kg/day and reached 25 mg/kg/day on day 9 and 50 mg/kg/day on day 29 (eFigure 2 in Supplement 1). The number and type of seizures and status epilepticus episodes were reported daily using an interactive voice-response system, and adverse events and medications were recorded using a paper-based diary. Details of the trial procedures are available in the protocol (Supplement 2). Patients who completed treatment were eligible to enter an open-label extension phase (NCT02544750). Patients who withdrew from the study or did not enter the open-label extension were seen at 4 weeks after the last dose. An independent safety monitoring committee approved the higher dosages used in this trial and monitored...
patient safety. An adjudication committee evaluated any potential signs of abuse.

**Outcome Measures**

The primary end point was the change from baseline in the number of TSC-associated seizures in patients taking add-on cannabidiol vs placebo during the 16-week treatment period. The primary end point, TSC-associated seizures, included countable focal motor seizures without impairment of awareness, focal seizures with impairment of awareness, focal seizures evolving to bilateral motor seizures, and generalized seizures (tonic-clonic, tonic, clonic, or atonic); this excluded absence, myoclonic, and focal sensory seizures and infantile/epileptic spasms. A mean of 94% of patients’ baseline seizures were classified as TSC-associated seizures. This functional definition and classification of the primary-end-point, TSC-associated seizures was reviewed and approved by the US Food and Drug Administration, the European Medicines Agency, and the Epilepsy Study Consortium independent committee of experts.

Key secondary outcomes included the proportion of patients who had at least a 50% reduction from baseline in primary-end-point seizures; the participants’ or caregivers’ global impressions of change from baseline in overall condition, as assessed on a 7-point Likert scale that included 3 categories for improvement (ie, slightly improved, much improved, and very much improved), 3 for worsening (slightly worse, much worse, and very much worse), and an option to indicate no change; and the change from baseline in total seizures (ie, sum of all individual seizure types). Other secondary outcomes are described in the eMethods in Supplement 1. We also conducted a prespecified analysis to explore the effect of concomitant clobazam on the change in primary-end-point seizures.

**Statistical Analysis**

We assumed a reduction from baseline in seizures of 15% for placebo and 50% for cannabidiol with a common SD of 60%, leading to a sample size of 70 patients per treatment group with 90% power to detect a difference in response distributions. The primary analyses for all outcomes used the intention-to-treat data set, which included all randomized patients. The per-protocol data set, including patients who completed the study without major protocol deviations, was used in sensitivity analyses for the primary and key secondary outcomes. All statistical tests were 2-sided with a 5% significance level.

Negative binomial regression on the sum of the seizure counts during the treatment period was used for the primary outcome analysis and is described in the eMethods in Supplement 1, along with a description of statistical analyses used for all secondary outcomes. Type I error was controlled by a hierarchical gatekeeping procedure (eTable 2 in Supplement 1), wherein each successive end point was tested for inferential statistical significance only if the preceding comparison was statistically significant; otherwise, resultant P values were designated as nominal and used descriptively. All statistical analyses were done using SAS version 9.3 or higher (SAS Institute), and the threshold of significance was P < .05.

**Results**

**Patients**

Between April 6, 2016, and October 4, 2018, 255 patients were assessed for eligibility at 46 sites; 224 patients (median [range] age, 11.4 [1.1-56.8] years; 93 female patients [41.5%]) underwent randomization (US, 112; Poland, 61; Australia, 24; Spain, 11; the Netherlands, 9; UK, 7) to the CBD25 group (n = 75), the
CBD50 group (n = 73), and the placebo group (n = 76) (Figure 1). Not all patients reached or remained at their assigned dosage (eTable 3 in Supplement 1); 87% (65 of 75 patients) in the CBD25 group and 53% (39 of 73 patients) in the CBD50 group were receiving their target dosage at treatment end. The mean of each patient’s modal dosage was 24 mg/kg/day in the CBD25 group and 36 mg/kg/day in the CBD50 group.

Overall, the following 23 patients (10.3%) discontinued treatment and were excluded from the per-protocol analysis set: 12 (16%) in the CBD50 group, 10 (13%) in the CBD25 group, and 1 (1%) in the placebo group. Sixteen of 22 patients taking cannabidiol had an adverse event as the primary reason for discontinuation. Overall, 201 patients completed treatment; of those, 199 (99%) entered the open-label extension trial.

Baseline characteristics were similar between the treatment groups (Table 1). Patients had previously discontinued a median (range) of 4 (0-15) antiepileptic drugs and were concurrently taking a median (range) of 3 (0-5) antiepileptic drugs. The median (interquartile range [IQR]) number of primary–end-point seizures was 56.9 (28.5-107.4) in the 4-week baseline period.

Primary Outcome
A reduction from baseline in primary–end-point seizures of 48.6% (95% CI, 40.4%-55.8%) was observed for the CBD25 group, 47.5% (95% CI, 39.0%-54.8%) for the CBD50 group, and 26.5% (95% CI, 14.9%-36.5%) for the placebo group during the treatment period (Figure 2A). The percentage reduction from
placebo was 30.1% (95% CI, 13.9%-43.3%; P < .001) for the CBD25 group and 28.5% (95% CI, 11.9%-42.0%; nominal P = .002) for the CBD50 group. During the maintenance period, patients had a 36.9% reduction in primary–end-point seizures from placebo for both the CBD25 and the CBD50 groups. The percentage reduction from baseline in primary–end-point seizures was 48.1% (95% CI, 39.8%-55.3%) for the CBD25 group, 47.6% (95% CI, 39.3%-54.8%) for the CBD50 group, and 26.9% (95% CI, 15.4%-36.8%) for the placebo group during the full treatment period; 4 patients in the CBD25 group, 2 in the CBD50 group, and none in the placebo group were seizure free during the full treatment period; 4 patients in the CBD25 group was seizure free during the full treatment period; 4 patients in the CBD50 group, and none in the placebo group were seizure free during the maintenance period.

At treatment end, 48 of 70 patients (69%) in the CBD25 group, 43 of 69 patients (62%) in the CBD50 group, and 30 of 76 patients (39%) in the placebo group reported improvement from baseline in overall condition, according to the participants’ or caregivers’ global impression of change (eFigure 6 in Supplement 1). The odds ratios were 2.25 (95% CI, 1.24-4.07; nominal P = .007) for CBD25 vs placebo and 1.77 (95% CI, 0.98-3.20; nominal P = .06) for CBD50 vs placebo.

The percentage reduction from baseline in total seizures was 48.1% (95% CI, 39.8%-55.3%) for the CBD25 group, 47.6% (95% CI, 39.3%-54.8%) for the CBD50 group, and 26.9% (95% CI, 15.4%-36.8%) for the placebo group during the maintenance period (Figure 2A). During the maintenance period, a 35.6% (95% CI, 17.1%-50.0%) reduction in total seizures compared...
Adverse Events

Adverse events were reported by 70 patients (93%) in the CBD25 group, 73 patients (100%) in the CBD50 group, and 72 patients (95%) in the placebo group; 88% of the adverse events were mild or moderate. The most common adverse events in the cannabidiol groups were diarrhea (placebo group, 19 [25%]; CBD25 group, 23 [31%]; CBD50 group, 41 [56%]), somnolence (placebo group, 7 [9%]; CBD25 group, 10 [13%]; CBD50 group, 19 [26%]), decreased appetite (placebo group, 9 [12%]; CBD25 group, 15 [20%]; CBD50 group, 17 [23%]), and liver transaminase level elevations (alanine aminotransferase level increased: placebo group, 0; CBD25 group, 9 [12%]; CBD50 group, 16 [22%]; aspartate aminotransferase level increased: placebo group, 0; CBD25 group, 8 [11%]; CBD50 group, 14 [19%]).

In patients taking CBD with clobazam vs without clobazam, somnolence (placebo: 3 of 25 [12%] vs 4 of 51 [8%]; CBD25, 5 of 17 [29%] vs 5 of 58 [9%]; CBD50, 10 of 19 [53%] vs 9 of 54 [17%]), rash (placebo: 2 of 25 [8%] vs 0 of 51; CBD25, 2 of 17 [12%] vs 2 of 58 [3%]; CBD50, 1 of 19 [5%] vs 6 of 54 [11%]), and pneumonia (placebo, 0 of 25 vs 1 of 51 [2%]; CBD25, 2 of 17 [12%] vs 0 of 58; CBD50, 1 of 19 [5%] vs 1 of 54 [2%]) generally occurred more frequently (eTable 5 in Supplement 1).

An adverse event was listed as one of the reasons for treatment discontinuation in 20 patients (CBD25, 8 [11%]; CBD50, 10 [14%]; placebo, 2 [3%]); most common adverse events leading to discontinuation were rash (CBD25 group, 2 patients [3%]; CBD50 group, 2 patients [3%]); alanine aminotransferase level elevations, somnolence, and urticaria (2 patients [3%] each in the CBD50 group). Nine patients (12%) in the CBD25 group, 21 (29%) in the CBD50 group, and 4 (5%) in the placebo group had permanent dosage reductions because of an adverse event, most commonly diarrhea (placebo group, 1 [1%]; CBD25 group, 2 [3%]; CBD50 group, 7 [10%]) (eTable 6 in Supplement 1).

Serious adverse events were reported in 28 patients (CBD25, 16 [21%]; CBD50, 10 [14%]; placebo, 2 [3%]); liver enzyme level elevations were the most frequent serious adverse events (eTable 7 in Supplement 1). No deaths were reported.

Serum aminotransferase level elevations greater than 3 times the upper limit of the normal range occurred in 28 of 148 patients (18.9%) taking cannabidiol (CBD25, 9 of 75 [12%]; CBD50, 19 of 73 [26%]) and no patient taking a placebo; 22 of 28 affected patients (79%) were taking concomitant valproate (eTable 8 in Supplement 1). Most elevations occurred within 30 days of starting treatment and resolved either spontaneously, following treatment discontinuation, or after cannabidiol or antiepileptic drug dosage reduction (eTable 9 in Supplement 1). No patient met the Hy’s Law criteria for drug-induced liver injury. Additional safety, tolerability, and laboratory parameters are included in the eResults in the Supplement 1.

Discussion

This is the first randomized clinical trial to assess add-on cannabidiol in a disorder with primarily focal seizures, and the efficacy results are consistent with those from the 4 prior phase 3 trials of cannabidiol in the treatment of Lennox-Gastaut and Dravet syndromes.18,20,21,23 Our trial included patients younger than 2 years and used a much higher dosage of cannabidiol, with an accelerated titration than previously tested. Patients in this study had frequent and highly treatment-resistant seizures; cannabidiol was their eighth attempted medication on average. Nonetheless, cannabidiol led to meaningful reductions in seizures vs placebo observed as early as the titration period and maintained throughout the study. Importantly, patients and caregivers perceived meaningful improvement in overall condition, evident by participants’ and caregivers’ global impressions of change scores and enrollment in the open-label extension phase.
Given the bidirectional drug-drug interaction between cannabidiol and clobazam, in which exposure of the active metabolite of each agent is increased, it is important to understand the clobazam-independent efficacy of cannabidiol. This trial supports cannabidiol’s independent efficacy, because most patients (73%) were not taking clobazam, and cannabidiol was significantly more efficacious than placebo. Furthermore, although subgroup analyses from individual studies should be interpreted with caution, the treatment effect remained evident in the subgroup without clobazam. Cannabidiol administration has been shown to increase levels of mTOR inhibitors everolimus and sirolimus and calcineurin

---

### Table 2. Common Adverse Events Among Patients in the Safety Analysis Set

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Treatment group, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (n = 76)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>19 (25)</td>
</tr>
<tr>
<td>Mild</td>
<td>16 (21)</td>
</tr>
<tr>
<td>Moderate</td>
<td>3 (4)</td>
</tr>
<tr>
<td>Severe</td>
<td>0</td>
</tr>
<tr>
<td>Somnolence</td>
<td>7 (9)</td>
</tr>
<tr>
<td>Mild</td>
<td>6 (8)</td>
</tr>
<tr>
<td>Moderate</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Severe</td>
<td>0</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>9 (12)</td>
</tr>
<tr>
<td>Mild</td>
<td>9 (12)</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
</tr>
<tr>
<td>Severe</td>
<td>0</td>
</tr>
<tr>
<td>Alanine aminotransferase level increased</td>
<td>0</td>
</tr>
<tr>
<td>Mild</td>
<td>0</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
</tr>
<tr>
<td>Aspartate aminotransferase level increased</td>
<td>0</td>
</tr>
<tr>
<td>Mild</td>
<td>0</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
</tr>
<tr>
<td>Vomiting</td>
<td>7 (9)</td>
</tr>
<tr>
<td>Mild</td>
<td>7 (9)</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
</tr>
<tr>
<td>Severe</td>
<td>0</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>6 (8)</td>
</tr>
<tr>
<td>Mild</td>
<td>4 (5)</td>
</tr>
<tr>
<td>Moderate</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>12 (16)</td>
</tr>
<tr>
<td>Mild</td>
<td>12 (16)</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
</tr>
<tr>
<td>γ-Glutamyltransferase level increased</td>
<td>0</td>
</tr>
<tr>
<td>Mild</td>
<td>0</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
</tr>
<tr>
<td>Seizure</td>
<td>5 (7)</td>
</tr>
<tr>
<td>Mild</td>
<td>4 (5)</td>
</tr>
<tr>
<td>Moderate</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Severe</td>
<td>0</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>10 (13)</td>
</tr>
<tr>
<td>Mild</td>
<td>8 (11)</td>
</tr>
<tr>
<td>Moderate</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Constipation</td>
<td>6 (8)</td>
</tr>
<tr>
<td>Mild</td>
<td>6 (8)</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
</tr>
<tr>
<td>Cough</td>
<td>5 (7)</td>
</tr>
<tr>
<td>Mild</td>
<td>5 (7)</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
</tr>
</tbody>
</table>

Abbreviations: CBD25, cannabidiol 25 mg/kg/day; CBD50, cannabidiol 50 mg/kg/day.

* Adverse events occurring in at least 10% of patients in any of the treatment groups are reported.
* Liver enzyme level elevations include only those reported as an adverse event; see eTable 8 in Supplement 1 for all elevations regardless of adverse event status. Severity of an adverse event was determined by the investigators and did not involve independent adjudication.
inhibitor tacrolimus. Therefore, use of cannabidiol as an adjunctive treatment in patients taking these medications may necessitate dosage adjustments; no patient in this study was taking concomitant mTOR inhibitors.

The cannabidiol dosage range of 25 to 50 mg/kg/day used in this study was informed by data from a cohort of patients with TSC (N = 18) in an expanded access program with the same cannabidiol formulation. In this study, both dosages showed similar efficacy but differing safety profiles. The safety profile of the 25 mg/kg/day dosage was consistent with the highest dosage (20 mg/kg/day) tested in prior trials; however, dosages greater than 25 mg/kg/day were associated with higher incidences of certain adverse and serious adverse events, with half of the patients randomized to 50 mg/kg/day unable to reach or maintain that dosage. Given the high proportion of patients in the CBD50 group who were not actually taking 50 mg/kg/day, we performed multiple sensitivity analyses excluding these patients, and there was still no difference in efficacy between the CBD25 and the CBD50 groups.

The most frequent adverse event leading to withdrawal were transient liver enzyme level elevation. The known potential for drug-induced liver injury with cannabidiol, as defined by an alanine aminotransferase level elevation greater than 5 times the upper limit of the normal range, especially with concomitant valproate, was confirmed in this study. Transaminase level elevations were more pronounced in patients taking concomitant valproate and/or 50 mg/kg/day of cannabidiol and those with baseline alanine aminotransferase elevations. All patients with drug-induced liver injury recovered, and none of the elevations in bilirubin levels met the Hy’s Law criteria. Overall, cannabidiol had an acceptable safety profile, with the clinical trial physicians managing adverse events associated with the accelerated titration scheme in this study by dosage reduction or treatment discontinuation.

Limitations
This trial is not without limitations. Because most patients in this trial were taking multiple medications, the potential for drug-drug interactions and their effect on safety and efficacy should be explored further. Although seizure type classification in this trial was confirmed by the Epilepsy Study Consortium, no video-electroencephalographic confirmation of the individual seizure subtypes was obtained. Potentially because of enhanced expectations for cannabidiol treatment, a higher than expected placebo effect was observed; however, this did not affect statistical significance of the treatment effect. Finally, long-term evaluation of cannabidiol in patients with TSC is needed and will be conducted in the ongoing open-label extension trial.

Conclusions
In patients with TSC and a high baseline burden of treatment-resistant, primarily focal seizures, add-on cannabidiol significantly reduced seizure frequency compared with placebo. The safety profile in this study is consistent with prior Lennox-Gastaut and Dravet syndrome studies, with confirmation of cannabidiol-associated risks of transaminase level elevations (especially in the presence of valproate) and somnolence and sedation (especially in the presence of clobazam).

ARTICLE INFORMATION
Accepted for Publication: October 4, 2020.
Published Online: December 21, 2020.

Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2020 Thiele EA et al. JAMA Neurology.

Author Affiliations: Pediatric Epilepsy Program, Massachusetts General Hospital, Boston (Thiele); Department of Neurology and Pediatrics, University of Alabama School of Medicine, Birmingham (Bebin); Centro Médico Teknon, Neurocenter Barcelona, Barcelona, Spain (Bhathal); Department of Pediatric Neurology, Brain Center University Medical Center, Utrecht, the Netherlands (Jansen); Department of Neurology and Epileptology, The Children’s Memorial Health Institute, Warsaw, Poland (Kotulska); EpiCare: A European Reference Network for Rare or Low Prevalence Complex Diseases, Bron, France (Kotulska); Neurology Department, Sydney Children’s Hospital, Randwick, Australia (Lawson); Neurosciences Unit, UCL Institute of Child Health, London, United Kingdom (O’Callaghan); Department of Neurology, Washington University School of Medicine, St Louis, Missouri (Wong); Greenwich Biosciences Inc, Carlsbad, California (Sahebkar; Knappertz); GW Research Ltd, Cambridge, United Kingdom (Checketts).

Author Contributions: Drs Thiele and Knappertz had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Thiele, Jansen, Kotulska, O’Callaghan, Checketts.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Bhathal, Jansen, Lawson, Wong, Sahebkar, Checketts, Knappertz.
Critical revision of the manuscript for important intellectual content: Thiele, Bebin, Bhathal, Jansen, Kotulska, Lawson, O’Callaghan, Wong, Sahebkar, Knappertz.
Statistical analysis: Checketts, Knappertz.
Administrative, technical, or material support: Jansen, Sahebkar.
Supervision: Thiele, Bhathal, Jansen, Sahebkar, Knappertz.
Conflict of Interest Disclosures: Dr Thiele received support from GW Research Ltd as a site principal investigator during the conduct of the trial, outside of the current work, Dr Thiele serves as a principal investigator on clinical trials for GW Research Ltd and Zogenix and as a consultant for Aquestive Therapeutics, Biocodex, West Therapeutics, Greenwich Biosciences, and Zogenix. Dr Bebin received support from GW Research Ltd as a site principal investigator during the conduct of the trial and serves as a consultant for Greenwich Biosciences and Biocodex. Dr Jansen was a site principal investigator on this trial. Dr Bhathal reported having participated as a principal investigator in the clinical trials used as data for this article. Dr Kotulska reported personal fees and nonfinancial support from GW Pharmaceutical Companies during the conduct of the study. Dr Lawson reported grants from GW Pharmaceutical Companies during the conduct of the study. Dr O’Callaghan reported personal fees from GW Pharmaceutical Companies during the conduct of the study and personal fees from Novartis outside the submitted work. Dr Wong was a site principal investigator on this trial, for which his institution received support from GW Research Ltd. Dr Sahebkar is a full-time employee of Greenwich Biosciences. Mr Checketts is a full-time employee of GW Research Ltd and reports other support from GW Pharmaceutical Companies outside the submitted work. Dr Knappertz is a full-time employee of Greenwich Biosciences and owns shares in the company. In addition, Dr Knappertz had a patent to Use of Cannabinoids in the Treatment of Epilepsy issued and had additional related patents pending (WO2019097238, WO2019106386, WO2019064031, and WO2019145700), as well as unpublished patent documents PCT/GB2019/051173, GB1818935.7, GB1819573.5, GB1900797.0, GB1902427.2, GB19062631, GB1907283.4, and GB1910803.4). No other disclosures were reported.
Funding/Support: The study was supported by GW Research Ltd.
Role of the Funder/Sponsor: GW Research Ltd was responsible for the design and conduct of the study (including input from investigators and other experts); the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This included management, monitoring, pharmacovigilance, data analysis, and study medication supply. The trial protocol and procedures were reviewed prior to trial start at investigators’ meetings. Third-party services were used for clinical and bioanalytical laboratory analyses; case report form design; data management; trial medication distribution, returns, and destruction; an interactive voice-response system; seizure type classification; and translation of documents.

Group Information: Members of the GWPCARE6 Study Group are listed in Supplement 3.

Meeting Presentation: Data from this study were previously presented at the American Epilepsy Society Annual Meeting, December 7, 2019; Baltimore, Maryland.


Additional Contributions: The authors would like to thank the patients, their families, and the sites that participated in this trial sponsored by GW Research Ltd, a GW Pharmaceuticals PLC company. Medical writing and editorial support were provided by Ritu Pathak, PhD, and Mary Kacillas, Ashfield Healthcare Communications, and was funded by GW Research Ltd.

REFERENCES


